News

Inhibikase Receives Orphan-Drug Designation for risvodetinib in Multiple System Atrophy

1 Mins read

Shares of Inhibikase Therapeutics surged in premarket trading on Wednesday following the company’s recent acquisition of orphan-drug designation from the U.S. Food and Drug Administration (FDA) for its flagship program, risvodetinib. This medical breakthrough is specifically aimed at treating multiple system atrophy (MSA), a rare and incurable neurological disease known for its degenerative effect on certain brain regions.

At present, there are no FDA-approved therapeutic interventions available to address the symptoms or modify the progression of MSA. The orphan-drug program by the FDA grants special recognition to drugs and biologics designed to tackle diseases and disorders that impact fewer than 200,000 individuals in the United States. Moreover, this designation provides the drugs with an extended period of marketing exclusivity, protecting them against potential competitors.

Inhibikase Therapeutics is currently focused on advancing its animal-model studies to explore the therapeutic potential of risvodetinib in blocking the progression of MSA as well as potentially reversing functional loss associated with this debilitating neurological condition.

The shares of Inhibikase skyrocketed by 22% in premarket trading, reaching $1.71 per share from their previous closing price of $1.40.

Related posts
News

Trump Media & Technology Group: Trump Media Reports First Quarter 2025 Results

4 Mins read
~ Ended First Quarter with $759.0 Million in Cash/Investments ~Trending NowBest Forex Trading Robots To Invest In 2022 ~ Operations Consumed Just…
News

Ethereum Explodes 25% Higher To $2,400, Notches Largest 1-Day Gain In 4 Years

1 Mins read
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.Trending NowBest Forex Trading Robots To…
News

FioBit's Ultimate Dogecoin Cloud Mining Guide for 2025: Secure DOGE Investment Without Hardware Using the Most Trusted Crypto Mining Provider to Hedge Against Bitcoin Drops | Business Upturn

2 Mins read
Sydney, Australia , May 08, 2025 (GLOBE NEWSWIRE) — As Bitcoin continues to experience short-term volatility in 2025, a growing number of…

Leave a Reply

Your email address will not be published. Required fields are marked *

82 + = 83